Actively Recruiting
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer, an Exploratory Non-intervention Study.
Led by University Hospital, Basel, Switzerland · Updated on 2026-05-12
35
Participants Needed
2
Research Sites
258 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality. Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality. Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.
CONDITIONS
Official Title
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer, an Exploratory Non-intervention Study.
Who Can Participate
Eligibility Criteria
You may qualify if you...
All patients > 18 years of age, able to give informed consent as documented by signature, with a cystoscopically proven bladder cancer, suspicious for T1 stage, estimated by the treating physician, who will undergo TUR-B
You will not qualify if you...
Patients with metastases or concomitant upper tract tumor at diagnosis will be excluded, Patients with non T1 G3 cancers will be excluded from the study and no further sampling and analyses will take place. Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy will be excluded for further ct-DNA sampling, Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. Vulnerable persons (e.g. < 18y of age, unable to consent to the study)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Universitätsspital Basel
Basel, Switzerland
Actively Recruiting
2
Luzerner Kantonsspital
Lucerne, Switzerland
Actively Recruiting
Research Team
H
Heike Püschel
CONTACT
N
Niklas Simon
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here